--- title: What Medicare's GLP-1 expansion reveals about the future of payer access description: Discover how Medicare's GLP-1 expansion impacts future payer access, real-world evidence generation, and the landscape of high-cost therapies. image: https://blog.healthverity.com/hubfs/New%20HV%20Blogs%20July%202026/Navigating%20the%20impacts%20of%20the%20Inflation%20Reduction%20Act%20Strategic%20considerations%20for%20pharma.webp --- Announcing HealthVerity Precision Event Alerts, a next-generation physician alerting solution. [Learn more](https://healthverity.com/news/healthverity-precision-event-alerts-launch/) - [Contact](https://healthverity.com/contact/) - [Sign In](https://marketplace.healthverity.com/login/?next=/marketplace/) [![HealthVerity-Logo-Dark-3](https://blog.healthverity.com/hs-fs/hubfs/HealthVerity-Logo-Dark-3.png?width=1662&height=320&name=HealthVerity-Logo-Dark-3.png)](https://healthverity.com/) - How We Help - Featured Content - [HealthVerity MarketplaceTM](https://healthverity.com/marketplace/healthverity-marketplace/) - [HealthVerity TaxonomySM](https://healthverity.com/taxonomy-portal/) - [Life Sciences](https://healthverity.com/life-sciences/) - [Identity Manager (HVID)](https://healthverity.com/identity-manager/) - Data Ecosystem - [HealthVerity MarketplaceTM](https://healthverity.com/marketplace/healthverity-marketplace/) - [HealthVerity TaxonomySM](https://healthverity.com/taxonomy-portal/) - [Precision Event Alerts](https://healthverity.com/precision-event-alerts/) - [HealthVerity Mastersets](https://healthverity.com/mastersets/portal/) - [Media Measurement](https://healthverity.com/media-measurement/) - [Insurance Underwriting](https://healthverity.com/insurance-underwriting/) - Technology Products - [Identity Manager (HVID)](https://healthverity.com/identity-manager/) - [HealthVerity FLOW](https://healthverity.com/flow/portal/) - [Governance Manager](https://healthverity.com/governance-manager/) - [Smart Contracts](https://healthverity.com/smart-contracts-manager/) - Symphony - Symphony Health Platform - [Symphony Health Overview](https://healthverity.com/symphony-health/overview/) - [Integrated Dataverse](https://healthverity.com/symphony-health/integrated-dataverse-and-source-solutions/) - [Symphony HealthCloud](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/) - Symphony Solutions - [Health technology and business intelligence solutions](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/) - [Integrated Dataverse and Source Solutions](https://healthverity.com/symphony-health/integrated-dataverse-and-source-solutions/) - [Brand strategy and sales](https://healthverity.com/symphony-health/optimize-brand-strategy-and-sales-effectiveness/) - [HealthRankings](https://healthverity.com/symphony-health/health-rankings/) - [Market access](https://healthverity.com/symphony-health/solve-market-access-challenges/) - [Patient Journey](https://healthverity.com/symphony-health/understand-the-patient-journey/) - [Medicines affordability](https://healthverity.com/symphony-health/making-medicines-more-affordable/) - Symphony Products - [PayerSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PayerSource.pdf) - [PrescriberSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PrescriberSource.pdf) - [PatientSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PatientSource.pdf) - [PatientSourceCompleteTM](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PatientSourceComplete.pdf) - [PatientSourceDUOTM](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PatientSourceDUO.pdf) - [Symphony FLEXTM](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-Symphony-FLEX.pdf) - [CustomerSource®](https://healthverity.com/symphony-health/integrated-dataverse-and-source-solutions/) - [DiagnosticSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-DiagnosticSource.pdf) - [NonRetailSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-NonRetailSource.pdf) - Symphony Technology - [Symphony HealthCloud](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/) - [Synoma Data Integration](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/) - [Vantage Applications](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-Vantage-Applications.pdf) - [Metys](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/metys/) - Who We Serve - [Life Sciences](https://healthverity.com/life-sciences/) - [Government](https://healthverity.com/government/) - [Insurance](https://healthverity.com/insurance/) - [Channel Partners](https://healthverity.com/channel-partners/) - [Data Ecosystem Partners](https://healthverity.com/data-ecosystem-partners/) - Resources - [HealthVerity Blog](https://blog.healthverity.com/) - [News & Events](https://healthverity.com/resources/news-and-events/) - [Resource Library](https://healthverity.com/resources/resource-library/) - [Publications](https://healthverity.com/resources/publications/) - [The IPGE Approach](https://healthverity.com/ipge-approach/) - [Zombie Data Explained](https://healthverity.com/get-verified/) - [Careers](https://healthverity.com/careers/) - [About Us](https://healthverity.com/about-us/) [Request Demo](https://healthverity.com/request-demo/) [Contact](https://healthverity.com/contact/) [Sign In](https://marketplace.healthverity.com/) [![Logo](https://blog.healthverity.com/hubfs/social-suggested-images/healthverity.comwp-contentuploadshealthverity-2023-logo2x.png)](https://healthverity.com/) - How We Help - Symphony - Who We Serve - Resources - [Careers](https://healthverity.com/careers/) - [About Us](https://healthverity.com/about-us/) [Request Demo](https://healthverity.com/request-demo/) Featured Content ###### HealthVerity MarketplaceTM The nation’s largest healthcare and consumer data ecosystem ###### taXonomy Pathways Unique features per therapeutic area with claims, labs and EHR including notes ###### HealthVerity eXOs AI-native real-world evidence generation ###### Identity Manager (HVID) Standalone de-identification as a service Data Ecosystem HealthVerity MarketplaceTM HealthVerity TaxonomySM HealthVerity Notes Precision Event Alerts HealthVerity Mastersets Media Measurement Syndicated Audiences Insurance Underwriting Technology Products Identity Manager (HVID) HealthVerity for Clinical Trial Linkage HealthVerity for Commercial Smart Contracts HealthVerity for Registries Symphony Health Platform ###### Symphony Health Overview Seamless Data. Stronger Insights. Smarter Decisions. ###### Integrated Dataverse Integrated Dataverse (IDV®) is de-identified claims data platform that combines medical, hospital, prescription, and demographic data into a single unifed view. ###### Symphony HealthCloud Securely store, integrate, access, and analyze virtually unlimited volumes of data with Symphony HealthCloud. Symphony Solutions Health technology and business intelligence solutions Integrated Dataverse and Source Solutions Brand strategy and sales HealthRankings Market access Patient Journey Medicines affordability Symphony Products PayerSource® PrescriberSource® PatientSource® PatientSourceCompleteTM PatientSourceDUOTM Symphony FLEXTM CustomerSource® DiagnosticSource® NonRetailSource® Symphony Technology Symphony HealthCloud Synoma Data Integration Vantage Applications Metys ###### Life Sciences Technology solutions from development through commercialization ###### Channel Partners HealthVerity enables partners to unlock unprecedented value and insights for clients ###### Government Comprehensive and compliant solutions to manage the nation’s care ###### Data Ecosystem Partners Join the nation’s largest data partner ecosystem ###### Insurance Insurance-grade solutions that excel in managing risk and rebates ###### HealthVerity Blog Insights and updates from industry experts ###### Publications Peer-reviewed research and discoveries ###### News & Events Stay informed about our latest announcements and happenings ###### The IPGE Approach Fundamentals that power everything that we do and every solution we offer ###### Resource Library Explore guides, webinars, and tools to enhance your understanding ###### Zombie Data Explained Learn how data quality drives better research outcomes [Thought Leadership](https://blog.healthverity.com/tag/thought-leadership), [Industry Updates](https://blog.healthverity.com/tag/industry-updates), [Government](https://blog.healthverity.com/tag/government) # What Medicare's GLP-1 expansion reveals about the future of payer access [By \- Clayton Hale, MS,](https://blog.healthverity.com/author/clayton-hale-ms) July 22, 2026 ![](https://blog.healthverity.com/hubfs/New%20HV%20Blogs%20July%202026/Navigating%20the%20impacts%20of%20the%20Inflation%20Reduction%20Act%20Strategic%20considerations%20for%20pharma.webp) ![clayton-hale-header](https://blog.healthverity.com/hs-fs/hubfs/clayton-hale-header.png?width=1600&height=333&name=clayton-hale-header.png) On July 1, 2026, the Centers for Medicare and Medicaid Services (CMS) launched the [Medicare Bridge demonstration](https://www.medicare.gov/publications/12234-medicare-glp-1-bridge-glp-1-drugs-for-50-a-month.pdf), extending GLP-1 access to certain Medicare beneficiaries. For manufacturers, Bridge is worth watching for reasons that have little to do with GLP-1 coverage itself. It is a live test of how Medicare and commercial payers will evaluate the next wave of high-cost therapies under the Inflation Reduction Act's (IRA) Part D redesign, which shifted more of the drug spend onto plans. The questions plans are actually asking are how persistent will patients be on therapy, and when will the downstream medical savings show up in claims? Clinical trial data cannot answer either, thus Bridge was designed to generate the real-world evidence that will. While the clinical story is settled the economic one still remains: **whether broader GLP-1 use lowers long-term spend enough to justify the upfront price, and whether payers capture that value for the patients they cover.** For manufacturers with high-cost therapies in the pipeline the commercial conversation is going to hinge on persistence and the medical offsets that show up, or *don't*, in real-world data. ## Why CMS created the Bridge program CMS initially planned to expand GLP-1 access through a voluntary model called BALANCE, which would have let Medicare Part D plans offer the drugs at discounted prices. Yet, not enough plans were signed on so CMS pivoted to the Bridge demonstration. The reason plans were held back was financial, because under the Part D restructuring from the IRA plans now carry more of the drug spend themselves. A high-demand category with uncertain persistence and long-tail medical offsets is exactly the kind of exposure actuaries cannot yet size. That is what Bridge is really about. CMS is letting evidence accumulate before committing Medicare to a permanent coverage decision. Once plans can see how long patients stay on these drugs and when the downstream savings actually land in claims, the coverage question becomes answerable. ## Real-world data in Medicare and evidence generation Bridge is, in many ways, a national evidence-generation initiative. Over the coming years, stakeholders will need to understand: - Which Medicare beneficiaries initiate GLP-1 therapy - How long they remain on treatment - Which comorbidities they present with and develop over the progression of their disease - How utilization differs across Medicare Advantage and standalone Part D plans - Whether improved outcomes translate into meaningful healthcare savings These insights will shape not only the future of GLP-1 coverage, but also Medicare's approach to future high-cost therapies. Manufacturers that can answer these questions early will be better positioned during payer negotiations, evidence generation, and value and market access planning. ## The need for longitudinal visibility in Medicare Manufacturers need longitudinal visibility that follows patients across therapies, benefit phases, and even payers while capturing their clinical and financial context. Understanding adherence, persistence, benefit progression, payer dynamics, coding practices, and total healthcare utilization provides a far more comprehensive picture of product value to secure payer access. As Medicare continues evolving, these insights will increasingly determine how therapies are evaluated, and ultimately reimbursed. ## Turning policy into actionable evidence The Bridge demonstration may be temporary, but the questions it seeks to answer are not. Future payer access decisions will increasingly depend on demonstrating where value occurs, when it occurs, and for whom. [Symphony Health, a HealthVerity company](https://healthverity.com/symphony-health/), combines comprehensive longitudinal claims with advanced payer analytics to help manufacturers answer those questions. ## HealthVerity and Symphony Health capabilities include: - **Part D benefit tracking** to model patient progression through deductible, coverage, and catastrophic phases, including parallel analysis of Bridge and traditional Part D claims. With the granular details collected through data suppliers, Symphony Health can differentiate claims from the Bridge program versus other Medicare payers. - **Low Income Subsidy (LIS) visibility** to better understand utilization and affordability across unique Medicare populations. - **Adherence and persistence analytics** to evaluate real-world treatment duration and its impact on long-term value. - **Detailed payer intelligence** that differentiates Medicare Advantage and standalone Part D dynamics. - **Patient journey profiling** that connects diagnoses, comorbidities, risk adjustment, and utilization into a more comprehensive view of payer behavior. - **Forecasting Medicare Part D Rebating** is a need across nearly all therapeutic drugs covered by Medicare and Symphony’s robust data can assist finance teams in forecasting this quarterly bill from CMS. ## Looking beyond GLP-1 medications The Bridge demonstration reflects a broader shift in how payers evaluate innovation. Tomorrow's market access decisions will depend on real-world evidence that connects clinical outcomes with utilization, economics, and patient behavior. Manufacturers that invest in that understanding today will be better prepared to navigate the reimbursement landscape of tomorrow. See how Symphony Health data can help you navigate the IRA and Part D redesign: [https://healthverity.com/symphony-health/making-medicines-more-affordable/](https://healthverity.com/symphony-health/making-medicines-more-affordable/)  [![HealthVerity and Symphony data can help you navigate the IRA and Part D redesign](https://no-cache.hubspot.com/cta/default/5412465/interactive-217076346249.png)](https://blog.healthverity.com/hs/cta/wi/redirect?encryptedPayload=AVxigLJmDXUZ1Q2tJS79IZS3WHxBK9sxvF6zU66Sqd%2FiGpNH1R6AUUy%2FUIMuaUF9sDbrJDK%2FhwgQKEJCOW7YcQTuxSpZTezRUskf5XiGFNg9yVa%2BdnffZf1hJjr7rs2N2sa4XcJGFS5Dq4T%2FCpnTN8fNohakWkCnsy3hZtXv5rBSMijui46VrspaFVL6l50gCHyXFpoZF19cGFxXwOmT6eOBKpNzIMs%3D&webInteractiveContentId=217076346249&portalId=5412465) [![HealthVerity and Symphony Health — the largest RWD data ecosystem](https://no-cache.hubspot.com/cta/default/5412465/interactive-214690873935.png)](https://blog.healthverity.com/hs/cta/wi/redirect?encryptedPayload=AVxigLJdaU6yOY9Ji4xUwsJ1xpYcRCiWuiXn6xVCZGa%2BS5tQQ66w9yfZMLS2x3PVAxKhBNjwQqB60jeUMomF702vIGsmcb5UG%2BwrmYbJzvgSLtXOrG4R0zkgOl4eLSxKPpRcUCodvOZqyOQsxzweWPqmbIgYML3dji4DnjejlDS%2BfbvVI8UtS9fwqMQzdGka%2BC3zvnWKgoc5vTHrjtGj&webInteractiveContentId=214690873935&portalId=5412465) ###### Category - [Solutions & Best Practices](https://blog.healthverity.com/tag/solutions-best-practices) - [Trends & Insights](https://blog.healthverity.com/tag/trends-insights) - [HEOR](https://blog.healthverity.com/tag/heor) - [Marketplace (RWD)](https://blog.healthverity.com/tag/marketplace-rwd) - [Thought Leadership](https://blog.healthverity.com/tag/thought-leadership) - [Industry Updates](https://blog.healthverity.com/tag/industry-updates) - [Open & Closed Claims](https://blog.healthverity.com/tag/open-closed-claims) - [Case Studies](https://blog.healthverity.com/tag/case-studies) - [Commercial Pharma](https://blog.healthverity.com/tag/commercial-pharma) - [Government](https://blog.healthverity.com/tag/government) - [AI](https://blog.healthverity.com/tag/ai) - [eXOs](https://blog.healthverity.com/tag/exos) - [Audiences](https://blog.healthverity.com/tag/audiences) - [taXonomy Pathways](https://blog.healthverity.com/tag/taxonomy-pathways) - [Clinical Notes](https://blog.healthverity.com/tag/clinical-notes) - [Rare Diseases](https://blog.healthverity.com/tag/rare-diseases) ###### Popular Post - [The GLP-1 trend: What the real-world data reveals](https://blog.healthverity.com/the-glp-1-surge-what-the-real-world-data-reveals) - [GLP-1 trends 2025: real-world data, patient outcomes & future therapies](https://blog.healthverity.com/glp-1-trends-2025-real-world-data-patient-outcomes-future-therapies) - [Open claims vs. closed payer claims: What’s the difference?](https://blog.healthverity.com/open-claims-vs-closed-payer-claims) - [An integrated approach for deeper insight with both open and closed claims data](https://blog.healthverity.com/an-integrated-approach-for-deeper-insight-with-both-open-and-closed-claims-data) - [GLP‑1 real‑world data for obesity: A new standard for metabolic care](https://blog.healthverity.com/glp-1-real-world-data-for-obesity-a-new-standard-for-metabolic-care) ###### Subscribe ### Similar Blogs [![GLP-1 trends 2025: real-world data, patient outcomes & future therapies](https://blog.healthverity.com/hs-fs/hubfs/Glp-1-alternative-2.png?width=352&name=Glp-1-alternative-2.png)](https://blog.healthverity.com/glp-1-trends-2025-real-world-data-patient-outcomes-future-therapies) #### [GLP-1 trends 2025: real-world data, patient outcomes & future therapies](https://blog.healthverity.com/glp-1-trends-2025-real-world-data-patient-outcomes-future-therapies) By [HealthVerity](https://blog.healthverity.com/author/healthverity) 26 August 2025 Few areas of medicine have captured public interest over the past two years quite like... [READ MORE](https://blog.healthverity.com/what-medicares-glp-1-expansion-reveals-about-the-future-of-payer-access) [![GLP‑1 real‑world data for obesity: A new standard for metabolic care](https://blog.healthverity.com/hs-fs/hubfs/glp-1-real%E2%80%90world-data-for-obesity-featured.png?width=352&name=glp-1-real%E2%80%90world-data-for-obesity-featured.png)](https://blog.healthverity.com/glp-1-real-world-data-for-obesity-a-new-standard-for-metabolic-care) #### [GLP‑1 real‑world data for obesity: A new standard for metabolic care](https://blog.healthverity.com/glp-1-real-world-data-for-obesity-a-new-standard-for-metabolic-care) By [HealthVerity](https://blog.healthverity.com/author/healthverity) 9 October 2025 The rise of GLP-1 therapies and the evolution of obesity treatment Over 40% of adults in the U.S.... [READ MORE](https://blog.healthverity.com/what-medicares-glp-1-expansion-reveals-about-the-future-of-payer-access) [![TrOOPs: Tracking cost implications under IRA Part D reforms](https://blog.healthverity.com/hs-fs/hubfs/New%20HV%20Blogs%20July%202026/Tallying%20the%20TrOOPs.webp?width=352&name=Tallying%20the%20TrOOPs.webp)](https://blog.healthverity.com/tallying-the-troops-tracking-cost-implications-under-ira-part-d-reforms) #### [TrOOPs: Tracking cost implications under IRA Part D reforms](https://blog.healthverity.com/tallying-the-troops-tracking-cost-implications-under-ira-part-d-reforms) By [Clayton Hale, MS](https://blog.healthverity.com/author/clayton-hale-ms) 10 July 2026 As part of its many provisions, the Inflation Reduction Act (IRA) includes a dramatic... [READ MORE](https://blog.healthverity.com/what-medicares-glp-1-expansion-reveals-about-the-future-of-payer-access) #### Who we serve - [Life Sciences](https://healthverity.com/life-sciences/) - [Government](https://healthverity.com/government/) - [Insurance](https://healthverity.com/insurance/) - [Channel Partners](https://healthverity.com/channel-partners/) - [Data Ecosystem Partners](https://healthverity.com/data-ecosystem-partners/) #### How we help - [HealthVerity Marketplace](https://healthverity.com/marketplace/) - [HealthVerity Mastersets](https://healthverity.com/mastersets/) - [HealthVerity FLOW](https://healthverity.com/flow/) - [The IPGE Approach](https://healthverity.com/ipge-approach/) #### Resources - [HealthVerity Blog](https://blog.healthverity.com/) - [News & Events](https://healthverity.com/resources/news-and-events/) - [Resource Library](https://healthverity.com/resources/resource-library/) - [Publications](https://healthverity.com/resources/publications/) #### Our company - [About Us](https://healthverity.com/about-us/) - [Leadership](https://healthverity.com/about-us/#leadership) - [Board of Directors](https://healthverity.com/about-us/#board) - [Careers](https://healthverity.com/careers/) - [Contact](https://healthverity.com/contact/) ©2026 HealthVerity, Inc.    |    [Terms & Conditions](https://healthverity.com/terms-and-conditions/)    |    [Privacy Policy](https://healthverity.com/privacy-policy/)